have a sub-optimal outcome if treated with standard chemotherapy. In the combination antiretroviral therapy (cART) era, in a randomised trial, the CR rate with CHOP+Rituximab was 46.6% in patients with aa-IPI 2-3. 3 Moreover, the 2-year overall survival (OS) of patients with IPI 41 was 50% in a phase II study 4 and 49% in patients with aa-IPI 3, in a pooled analysis of 1546 patients, during the more recent time period. 5 The use of high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) has shown clinical efficacy, acceptable toxicity 6, 7 and an unexpectedly low relapse rate, [8] [9] [10] in refractory/relapsed HIV-associated NHL (HIV-NHL). To evaluate the feasibility and efficacy of HDT in the frontline treatment of prognostically unfavourable HIV-NHL, we conducted a prospective multicenter study of ASCT as early consolidation after standard induction therapy, in patients classified at IPI high or high-intermediate risk. This trial is registered to www.ClinicalTrials.gov as NCT01045889.
HIV-infected patients with aggressive NHL, including diffuse large B-cell lymphoma, plasmablastic and anaplastic lymphoma, previously untreated, were eligible if they had an aa-IPI classification of 2 or 3, age 18-60 years and CD4 count higher than 50 cells/ μL (Supplementary Table S1 ). All patients had to be receiving cART or starting cART at study entry. The Institutional Review Board of each partecipating center approved the protocol and informed consent was obtained from each patients in accordance to the Declaration of Helsinki. Patients received CHOP-21 (CHOP-14 was allowed in plasmablastic lymphoma), plus Rituximab in CD20+ lymphoma, as induction therapy, with intrathecal methotrexate prophylaxis. After four courses, patients with CR or PR proceeded with two other courses and cyclophosphamide 4 g/m 2 plus G-CSF 10 μg/kg/day to collect stem cells (SCs), whereas patients with less than PR could receive salvage chemotherapy (ESHAP) before SC collection. All responding patients received HDT, according to BEAM conditioning regimen. 7 cART was maintained throughout the entire program. The primary end point for the trial was 2-year OS. We assumed an OS of 70% at 2 years, significantly > 50%, which is expected from the standard treatment with CHOP ± Rituximab in this patient population. 4 Using the optimal twostage design for phase II clinical trials, the number of patients for the first phase was 15. If at least 9/15 patients would be alive at 2 years, the study will continue until the enrollment of 43 total patients. The first step was successfully achieved. From January 2007 to January 2015, 27 patients were enrolled. The principal investigator in accordance with the Institutional Review Board decided to close the recruitment in May 2015, due to the slow enrolment, when 27 patients had been enrolled and the median follow-up exceeded 4 years.
Characteristics of the study population are shown in Table 1 . Seven patients withdrew before SC mobilization because of toxicity in five (cerebral hemorrage in one, prolonged cytopenia in one, repeated infections in one and hepatic failure in two hepatitis C virus-infected patients), progressive disease (PD) after cycle six in one (this patient achieved CR after salvage) and loss to follow-up in one (although in PR after salvage with ESHAP). Three/four patients who withdrew due to toxicity died (two with PD and one of hepatic failure), whereas one is still in CR. Overall, 15/27 patients (56%) achieved CR and 6 (22%) PR (ORR 78%) after the induction treatment. An adequate number of CD34+ cells (median 7.6 × 10 6 /kg) were obtained in 19/20 (95%) patients. Two patients had PD after SC collection and one was excluded from transplant because of cardiac failure. Finally, 16/27 patients (59%) received ASCT. Neutrophil engraftment occurred after 10 days (range 9-12) and platelet engraftment after 14 days (10-24). Twelve patients were in CR and four in PR before ASCT. Three patients received radiotherapy after transplant (one with testis involvement and two on previous bulky disease). One patient died on day +33 due to a carbapenemaseproducing Klebsiella pneumoniae sepsis. CR was documented after ASCT in the remaining 15 patients (Supplementary Figure S1) . After a median follow-up of 50 months after transplant (11-101), all patients are alive in continuous CR with both OS and PFS of 93.7% (95% confidence interval (CI) 63.2-99) (Figure 1a) . The main toxicities of HDT included grade 3-4 gastrointestinal event in eight patients, grade 3-4 hepatic in two and veno occlusive disease in one. Two patients suspended cART because of oral mucositis and restarted the same regimen after 1 and 2 weeks. With conventional antimicrobial prophylaxis and G-CSF support, infectious complications were mild and no systemic fungal infections occurred. Postengraftment complications during the first 2 years of observation included an asymptomatic CMV viremia and a fever of unknown origin in one patient, an acute cholecystitis, a bilateral pneumonia and two pneumonias in one patient. No patients required changes in cART regimen due to virological failure. At month 0, +3, +6, +12 and +24, the median CD4+ cell count was respectively 201 (range 51-269), 143 (45-346), 157 (62-353), 245 (99-687) and 455 cells/μL (142-729). Hepatitis C virus exacerbation was seen in one patient at month +36. On an intention to treat basis, 18/27 patients (67%) achieved CR. The 5-year OS of the entire series was 73.3% (95% CI 52-86.2) and the PFS 66.6% (95% CI 45.7-80.9), after a median follow-up of 58 months (5-108) (Figure 1b) . The comparison of the two groups of patients, who did or did not receive the transplant, showed that performance status 2, lymphoma stage IV, extranodal disease, aa-IPI 3, CD4+ cell count o200/μL, longer duration of HIV infection and not achieving CR after CHOP were all significantly associated with a reduced possibility of receiving the transplant (Supplementary Table S2 ). This is the first prospective trial addressing the role of HDT and ASCT in the front-line treatment of HIV-NHL. The CR rate (67%) and 5-year OS (73.3%) appear satisfactory. Transplant-related mortality was 6.25%, as a single patient died of sepsis. No significant detrimental effects on HIV infection were registered; HIV viremia remained undetectable in most patients and no cART failure occurred; excellent recovery of CD4+ cell count was seen and no opportunistic complications were recorded. Hence, ASCT can be considered feasible and well tolerated in the first-line setting. However, severely immunocompromised patients with o50 CD4+ cells/μL were excluded from this trial.
The complete absence of lymphoma relapse after a prolonged follow-up in the group of patients actually receiving the ASCT is remarkable and deserves consideration. Full recovery of immunologic function after ASCT 11 might be relevant to effectively control lymphomas that develope in a context of immunedeficiency. 12 Moreover, antitumor properties has been established for anti-HIV drugs 13 and immunomodulatory effects of protease inhibitors have been also suggested.
14 However, in our study 41% of patients could not receive ASCT. This was due to toxicity during the induction phase and early PD. Indeed, other prospective studies have shown that among HIV-infected patients with NHL, only 53-78% are able to complete the CHOP-Rituximab program. 3, 4, 15 Reducing the length of induction therapy could be an option to improve the rate of patients that could benefit of receiving the ASCT, avoiding early disease progression and reducing the load of toxicity
The results of this study could represent the rationale to further explore early treatment intensification in selected young patients with prognostically unfavourable aggressive HIV-NHL.
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